Merck Announces Clinical Holds on Studies Evaluating Islatravir for the Treatment and Prevention of HIV-1 Infection

KENILWORTH, N.J.--(BUSINESS WIRE) December 13, 2021 -- Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has placed clinical holds on the investigational new drug...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials